CAR-T cell therapy for hard-to-treat Graves' disease
Part of Eyes & vision, Hormones & metabolism, Immune system & allergy clinical trials.
This early-phase trial tests whether specially engineered immune cells (called CAR-T) can treat Graves' disease that hasn't responded to standard medication. It's for people with active, hard-to-control Graves' who have the TRAb antibody.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your Graves' disease has been hard to control — you've either been on medication for 3+ years or it has come back after stopping treatment.
- A blood test must show you have TRAb antibodies (a common sign of active Graves').
- You have no serious infections, heart problems, cancer, or history of severe allergic reactions.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You haven't joined another clinical trial in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called CAR-T cells made from a donor. The cells target B cells that may drive Graves' disease. It's for people whose Graves' disease has not gotten better with usual treatments.
This early-phase trial tests a new type of treatment called CAR-T cells (special immune cells made in a lab) to target and calm down the overactive immune system in people with severe Graves' disease that hasn't improved with standard medicines. It may offer a new option for those who have been on treatment for years or have had multiple relapses.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This trial is testing a new type of cell therapy called CAR-T that targets two proteins (CD19 and BCMA) on certain immune cells. It aims to help people with severe myasthenia gravis that has not improved with standard treatments.
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
This study tests a type of immunotherapy called CAR-T for people with certain autoimmune diseases that have not responded to standard treatments. It aims to see if this cell therapy can calm the overactive immune system.
Hear when a new Graves Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.